Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Witt

Showing results (171-180 of 242) with videos related to

Pageof 25
Sort By:
Acta Neuropathologica|March 23, 2011
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytomaHuriye Cin, Claus Meyer, Ricarda Herr, et al.
JCO Precision Oncology|June 26, 2023
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORMAnna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, et al.
Acta Neuropathologica|September 30, 2023
Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristicsRamin Rahmanzade, Elke Pfaff, Rouzbeh Banan, et al.
Nature Communications|February 25, 2021
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteomeSabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, et al.
Nature Immunology|September 15, 2025
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade gliomaAugusto Faria Andrade, Romain Sigaud, Evan Puligandla, et al.
Neuro-Oncology|July 26, 2022
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma modelsRomain Sigaud, Lisa Rösch, Charlotte Gatzweiler, et al.
Neuro-Oncology|August 17, 2022
BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytomaFlorian Selt, Romain Sigaud, Gintvile Valinciute, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2025
Comprehensive investigation of DNA damage repair genes in children with cancer identifies <i>SMARCAL1</i> as novel osteosarcoma predisposition geneNinad Oak, Wenan Chen, Alise Blake, et al.
Neuro-Oncology|October 11, 2017
Pediatric low-grade gliomas: next biologically driven stepsDavid T W Jones, Mark W Kieran, Eric Bouffet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2025
Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies <i>SMARCAL1</i> as a Novel Osteosarcoma Predisposition GeneNinad Oak, Wenan Chen, Alise Blake, et al.
Pageof 25

Showing results (171-180 of 242) with videos related to

Sort By:
Pageof 25
Acta Neuropathologica|March 23, 2011
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytomaHuriye Cin, Claus Meyer, Ricarda Herr, et al.
JCO Precision Oncology|June 26, 2023
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORMAnna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, et al.
Acta Neuropathologica|September 30, 2023
Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristicsRamin Rahmanzade, Elke Pfaff, Rouzbeh Banan, et al.
Nature Communications|February 25, 2021
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteomeSabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, et al.
Nature Immunology|September 15, 2025
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade gliomaAugusto Faria Andrade, Romain Sigaud, Evan Puligandla, et al.
Neuro-Oncology|July 26, 2022
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma modelsRomain Sigaud, Lisa Rösch, Charlotte Gatzweiler, et al.
Neuro-Oncology|August 17, 2022
BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytomaFlorian Selt, Romain Sigaud, Gintvile Valinciute, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2025
Comprehensive investigation of DNA damage repair genes in children with cancer identifies <i>SMARCAL1</i> as novel osteosarcoma predisposition geneNinad Oak, Wenan Chen, Alise Blake, et al.
Neuro-Oncology|October 11, 2017
Pediatric low-grade gliomas: next biologically driven stepsDavid T W Jones, Mark W Kieran, Eric Bouffet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2025
Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies <i>SMARCAL1</i> as a Novel Osteosarcoma Predisposition GeneNinad Oak, Wenan Chen, Alise Blake, et al.
Pageof 25